Peptides DB
Research-centric peptide and protocol reference hub
Study 38 of 41SS-31 literatureCirculation · ObservationalHigh-impact journal2024

Novel Role for Cardiolipin as a Target of Therapy to Mitigate Myocardial Injury Caused by Venoarterial Extracorporeal Membrane Oxygenation.

VA-ECMO appears to exacerbate myocardial injury by depleting cardiolipin, but the clinical implications of these findings require further investigation.

Read at CirculationAdd to compare

Where it sits

this study against the rest of the ss-31 corpus
3
Preclinical
29
Observational · this one
0
Open-label
4
Randomised
5
Reviews

Summary and findings

This study examined the role of cardiolipin in myocardial injury caused by venoarterial extracorporeal membrane oxygenation (VA-ECMO) in heart failure patients and swine models. It was found that VA-ECMO significantly reduced cardiolipin and tafazzin levels, leading to increased myocardial injury. The use of MTP-131 was shown to mitigate these effects.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Infarct size increased to 48±7% with VA-ECMO compared to 36±8% with reperfusion alone, P<0.001.2024

Abstract

The authors’ words, as Circulation supplied them

<h4>Background</h4>Cardiolipin is a mitochondrial-specific phospholipid that maintains integrity of the electron transport chain (ETC) and plays a central role in myocardial ischemia/reperfusion injury. Tafazzin is an enzyme that is required for cardiolipin maturation. Venoarterial extracorporeal membrane oxygenation (VA-ECMO) use to provide hemodynamic support for acute myocardial infarction has grown exponentially, is associated with poor outcomes, and is under active clinical investigation, yet the mechanistic effect of VA-ECMO on myocardial damage in acute myocardial infarction remains poorly understood. We hypothesized that VA-ECMO acutely depletes myocardial cardiolipin and exacerbates myocardial injury in acute myocardial infarction.<h4>Methods</h4>We examined cardiolipin and tafazzin levels in human subjects with heart failure and healthy swine exposed to VA-ECMO and used a swine model of closed-chest myocardial ischemia/reperfusion injury to evaluate the effect of VA-ECMO on cardiolipin expression, myocardial injury, and mitochondrial function.<h4>Results</h4>Cardiolipin and tafazzin levels are significantly reduced in the left ventricles of individuals requiring VA-ECMO compared with individuals without VA-ECMO before heart transplantation. Six hours of exposure to VA-ECMO also decreased left ventricular levels of cardiolipin and tafazzin in healthy swine compared with sham controls. To explore whether cardiolipin depletion by VA-ECMO increases infarct size, we performed left anterior descending artery occlusion for a total of 120 minutes followed by 180 minutes of reperfusion in adult swine in the presence and absence of MTP-131, an amphipathic molecule that interacts with cardiolipin to stabilize the inner mitochondrial membrane. Compared with reperfusion alone, VA-ECMO activation beginning after 90 minutes of left anterior descending artery occlusion increased infarct size (36±8% versus 48±7%; <i>P</i><0.001). VA-ECMO also decreased cardiolipin and tafazzin levels, disrupted mitochondrial integrity, reduced electron transport chain function, and promoted oxidative stress. Compared with reperfusion alone or VA-ECMO before reperfusion, delivery of MTP-131 before VA-ECMO activation reduced infarct size (22±8%; <i>P</i>=0.03 versus reperfusion alone and <i>P</i><0.001 versus VA-ECMO alone). MTP-131 restored cardiolipin and tafazzin levels, stabilized mitochondrial function, and reduced oxidative stress in the left ventricle.<h4>Conclusions</h4>We identified a novel mechanism by which VA-ECMO promotes myocardial injury and further identify cardiolipin as an important target of therapy to reduce infarct size and to preserve mitochondrial function in the setting of VA-ECMO for acute myocardial infarction.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Key findings

  • Not reported in abstract.
  • Not reported in abstract.
  • Not reported in abstract.

Limitations

  • Not reported in abstract.
  • Not reported in abstract.

Elsewhere in the SS-31 corpus

CMitochondrial dysfunction drives age-related degeneration of the thoracic aorta.GeroScience · 2026 · Not reported in abstract.AnimalCTargeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model.Circulation. Heart failure · 2026 · +173.2% single-fiber contractile function in soleus, p<0.001AnimalCReversal of Mitochondrial Transhydrogenase Causes Oxidative Stress in Heart Failure.Cell metabolism · 2015 · Not reported in abstract.AnimalCStructural and functional characterisation of the dextran utilisome from Bacteroides thetaiotaomicron.Journal of structural biology: X · 2026 · Not reported in abstract.In vitroC4-oxo-quinoline based fluorescent chemosensors for on-site detection of G-type nerve agent mimic DCP via spectroscopic and theoretical insights.Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy · 2026 · Limit of detection for DCP: 0.14 μM for 6DEQA.In vitroDEffectiveness of virtual reality-based rehabilitation on quality of life and upper extremity functions among stroke survivors: A systematic review and meta-analysis.International journal of nursing studies advances · 2026 · SMD = -0.09, 95% CI -0.30 to 0.11, p = .36; low certainty for QoL.review